November 06, 2013
1 min read
Save

Can-Fite granted patent for IOP-reducing drug candidate

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The U.S. Patent and Trademark Office has granted Can-Fite BioPharma U.S. patent No. 8,557,790 for an A3 adenosine receptor agonist to reduce IOP, according to a press release.

The patent relates to the use of the drug candidate CF101, an orally bioavailable A3 adenosine receptor agonist drug.

CF101 has demonstrated efficacy and safety in phase 2 clinical studies and is being developed by Can-Fite for dry eye syndrome (phase 3), glaucoma (phase 2) and uveitis (initiating phase 2), according to the release.

Pursuant to a license agreement between Can-Fite and OphthaliX’s wholly owned subsidiary, EyeFite, OphthaliX has exclusive rights to use and develop CF101 for the reduction of IOP in the U.S. until 2030, the release said.